Novo Nordisk A/S (NYSE:NVO) Trading Up 0.4%

Novo Nordisk A/S (NYSE:NVO)’s share price was up 0.4% during mid-day trading on Monday . The company traded as high as $138.20 and last traded at $137.59. Approximately 444,848 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 4,250,385 shares. The stock had previously closed at $137.00.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective for the company. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 19th. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Finally, Argus increased their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $145.17.

Novo Nordisk A/S Stock Up 0.1 %

The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $592.76 billion, a P/E ratio of 45.54, a price-to-earnings-growth ratio of 1.48 and a beta of 0.42. The company’s fifty day simple moving average is $133.74 and its 200 day simple moving average is $133.20.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). The business had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. Research analysts expect that Novo Nordisk A/S will post 3.11 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were paid a dividend of $0.5126 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio is currently 24.83%.

Institutional Trading of Novo Nordisk A/S

Institutional investors have recently made changes to their positions in the stock. Aveo Capital Partners LLC purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth approximately $205,000. 9258 Wealth Management LLC raised its stake in Novo Nordisk A/S by 4.0% during the 4th quarter. 9258 Wealth Management LLC now owns 2,513 shares of the company’s stock worth $260,000 after acquiring an additional 97 shares during the period. Rollins Financial raised its stake in Novo Nordisk A/S by 10.4% during the 4th quarter. Rollins Financial now owns 3,894 shares of the company’s stock worth $403,000 after acquiring an additional 368 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Novo Nordisk A/S by 38.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock worth $9,781,000 after acquiring an additional 26,067 shares during the period. Finally, Gryphon Financial Partners LLC bought a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $237,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.